Koers Orchid Pharma Limited Bombay S.E.
Aandelen
524372
INE191A01019
Farmaceutische producten
Omzet 2024 | 8,19 mld. 98,16 mln. 90,2 mln. | Omzet 2025 * | 10,28 mld. 123 mln. 113 mln. | Marktkapitalisatie | 53,99 mld. 647 mln. 594 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 922 mln. 11,05 mln. 10,15 mln. | Nettowinst (verlies) 2025 * | 1,49 mld. 17,8 mln. 16,36 mln. | EV/omzet 2024 | 6,31 x |
Nettoliquiditeiten 2024 | 1,32 mld. 15,82 mln. 14,54 mln. | Nettoliquiditeiten 2025 * | 1,65 mld. 19,74 mln. 18,14 mln. | EV/omzet 2025 * | 5,09 x |
K/w-verhouding 2024 |
72,1
x | K/w-verhouding 2025 * |
36,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 26,03% |
Recentste transcriptie over Orchid Pharma Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Manish Dhanuka
CEO | Chief Executive Officer | 56 | 31-03-20 |
Director of Finance/CFO | - | 29-06-20 | |
Kapil Dayya
CMP | Compliance Officer | - | 16/12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 74 | 31-03-20 | |
Mridul Dhanuka
BRD | Director/Board Member | 42 | 31-03-20 |
Manish Dhanuka
CEO | Chief Executive Officer | 56 | 31-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,47% | 749 mld. | |
+39,42% | 605 mld. | |
-6,35% | 351 mld. | |
+19,69% | 328 mld. | |
+8,80% | 292 mld. | |
+11,92% | 216 mld. | |
-2,62% | 214 mld. | |
+0,47% | 167 mld. | |
+6,46% | 165 mld. |